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Pain is common in gastroenterology. This review aims at giving an overview of pain mechanisms, clinical features, and treatment
options in oesophageal disorders. The oesophagus has sensory receptors speciﬁc for diﬀerent stimuli. Painful stimuli are encoded
by nociceptors and communicated via aﬀerent nerves to the central nervous system. The pain stimulus is further processed and
modulated in speciﬁc pain centres in the brain, which may undergo plastic alterations. Hence, tissue inﬂammation and long-
term exposure to pain can cause sensitisation and hypersensitivity. Oesophageal sensitivity can be evaluated ,for example, with the
oesophagealmultimodalprobe.Treatmentshouldtargetthecauseofthepatient’ssymptoms.Ingastro-oesophagealreﬂuxdiseases,
proton pump inhibitors are the primary treatment option, surgery being reserved for patients with severe disease resistant to drug
therapy.Functionaloesophagealdisordersaretreatedwithanalgesics,antidepressants,andpsychologicaltherapy.Lifestylechanges
are another option with less documentation.
1.Introduction
Pain and gastrointestinal (GI) discomfort are the leading
symptoms in the multitude of oesophageal disorders. In
oesophageal disorders, this review aims to (1) give an
overview of the mechanisms underlying abnormal pain
processing, (2) describe the clinical features of the most
relevant entities, and (3) give a summary of currently
recommended treatments.
2.Background
2.1. The Nociceptor and First-Order Neuron. Pain is deﬁned
as “an unpleasant sensory and emotional experience associ-
ated with actual or potential tissue damage or described in
t e r m so fs u c hd a m a g e ”[ 1]. Generally, noxious stimuli are
encoded by receptors (nociceptors) located in the organs.
When the nociceptor receives a noxious stimulus strong
enough to cause a depolarization, an action potential is
generatedandtransmittedalongtheﬁrst-orderneurontothe
dorsal horn of the spinal cord (Figure 1)[ 2].
Unlike cutaneous pain, most visceral nociceptors are
probably nonspeciﬁc (polymodal) and respond to diﬀer-
ent stimuli being, for example, mechanical, chemical, and
ischemic [3]. This information is mainly based on animal
studies. In humans, however, the oesophagus has also been
described to respond more or less to speciﬁc stimuli such
as electrical, mechanical, thermal, or chemical stimulation
[4, 5]. Animal experiments also show that aﬀerent nerve
ﬁbres may respond to either phasic or tonic distension of the
gut [6, 7], and this has to some degree been conﬁrmed in
human studies [8, 9]. Some ﬁbres—primarily the mucosal—
are adapting to a given stimulus and give no response when
thestimulusismaintained,whereasaﬀerentsinthemuscular
layers generally show less adaptation [6].
The principal temperature receptors in the oesophagus
are members of the transient receptor potential family.
Several temperature receptors exist, among others the2 Gastroenterology Research and Practice
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Figure 1: The anatomy and physiology of the pain stimulus. Pain is sensed in a nociceptor in the tissue, which generates an action potential
alongthenerveﬁbreoftheﬁrst-orderneuron.Theactionpotentialtravelsproximallytowardstheotherendoftheneuronandistransmitted
tothesecond-orderneuroninthespinalcordthroughasynapsemediated byneurotransmitters.Thesecond-orderneuronthengenerates an
action potential that travels further proximally through distinct nerve bundles (fasciculi) in the spinal cord and synapses to the third-order
neuron in the brain.
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Figure 2: The aﬀerent nerve supply of the gut. “True” visceral aﬀerents (white lines) innervate the gut and run temporarily together
with either the sympathetic or the parasympathetic nerves. During inﬂammation “silent aﬀerents” (dashed line) may become activated.
Gastrointestinal (GI) aﬀerents primarily project to the spinal cord or brain stem but can also “crosstalk” with the autonomic (grey line) or
enteric nervous system (ENS) through local or spinal reﬂexes.
transient receptor potential vanilloid 1 (TRPV1), whose
threshold for activation can be lowered by hydrogen ions
and inﬂammatory mediators [10]. Acid-sensitive receptors
in the gut consist mainly of three groups: TRPV1 (which
is temperature- as well as acid-sensitive), acid-sensing ion
channels (ASICs), and purino receptors [11]. Acid sensing is
important in subgroups of gastro-oesophageal reﬂux disease
(GORD) patients. For example, patients with nonerosive
reﬂux disease (NERD) and erosive reﬂux disease (ERD) are
hypersensitive, whereas patients with Barrett’s oesophagus
(BO) are hyposensitive to acid (see later sections) [12–15].
The aﬀerent ﬁbres of the ﬁrst order neuron are either
nonmyelinated (70–90%) or thinly myelinated ﬁbres. In
organs such as the pancreas and ureter the aﬀerents convey
only pain, whereas in others (oesophagus, stomach and
rectum)theaﬀerentsmediatepaintogetherwithothersensa-
tions [7, 16]. The visceral aﬀerents mediating conscious sen-
sations run predominantly together with nerves belonging
to the sympathetic nerves to reach the CNS, although
some aﬀerents join parasympathetic and other pathways
[17].
2.2. Organisation in the Spinal Cord. All the aﬀerent nerves
projecting to the spinal cord terminate in the dorsal horn.
From here, the stimulus transmits cephalad through the
spinal cord pathways and synapses to the third-order neuron
in the brain or brainstem [18] .T h e r ei sac l o s ei n t e r a c t i o n
and crosstalk between GI aﬀerents and those from the
somatic, autonomic, and enteric nervous systems (Figure 2)
[19]. Hence, the clinical impression of the patient can easily
be changed by complaints such as sweating and palpitations
relatedtotheautonomicnervoussystemaswellassymptoms
related to somatic referred pain (see later sections). A
partial explanation for this is the diﬀerent organisation
of aﬀerents innervating the organs as compared with the
somatic nervous system, see next section.Gastroenterology Research and Practice 3
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Figure 3: Visceral versus somatic innervation. The relatively low number of visceral aﬀerents terminate diﬀusely along several segments of
the spinal cord, whereas the high number of somatic aﬀerents terminate at one particular level. This is the reason for the diﬀuse localisation
of visceral pain.
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Figure 4:Left:viscerosomatichyperalgesia:eachsegmentinthespinalcordreceivesaﬀerentﬁbresfromvisceralaswellassomaticstructures.
viscero-somatichyperalgesiaorreferredpainoriginatesbecauseofthisconvergenceofspinalaﬀerents.Thebrainthereforeinterpretsthepain
asoriginatingfromasomaticstructurewiththesamesegmentalinnervation,forexample, referredpainintherightshoulderbecauseofpain
originatingfromthegallbladder.Referredpaincanbeenhancedbyspinalhyperexcitabilitycausedby,forexample,localinﬂammation,hence
causing a larger referred pain area. Right: viscero-visceral hyperalgesia: the convergence of visceral aﬀerent nerves in the spinal dorsal horn
from diﬀerent organs results in an increased nociceptive input to this particular segment of the spinal cord. Here shown with convergence
of aﬀerent nerves from the heart and gall bladder at the spinal level of Th5. This generates a stronger pain stimulus, a mechanism known as
viscero-visceral hyperalgesia.
The activity in the GI organs does not normally reach
the higher brain centres, except from information due to
ﬁlling of the oesophagus, stomach, and rectum. When the
organs are potentially in danger, for example due to diseases,
symptoms such as discomfort and pain are sensed. These
symptoms are typically vague and diﬃcult to characterise
and are often quite distinct from what is felt during noxious
diseases of the somatic system. The diﬀerence in the anatom-
ical structure of the two nervous systems explains why GI
pain is diﬀerent from the somatic counterpart. The visceral
aﬀerents are relatively few and terminate diﬀusely along
several segments of the spinal cord, whereas the relatively
numerous somatic aﬀerents terminate at one particular level
(Figure 3)[ 18].
The fact that each segment in the spinal cord receives
aﬀerent ﬁbres from visceral as well as somatic struc-
tures causes another phenomenon known as referred pain.
Although simpliﬁed, referred pain originates due to conver-
gencebetweenvisceralandsomaticﬁbresonthesamesecond
order (spinal) neuron (for details see [20]). Since the brain
cannot localise the precise origin of the visceral pain stimu-
lus, it may therefore interpret the pain as originating from
a somatic structure with the same segmental innervation
(Figure 4).
2.3. Innervation of the Oesophagus. The oesophagus is
dually innervated by vagal and spinal nerves (Figure 5).
Most aﬀerent ﬁbres run temporarily together with either4 Gastroenterology Research and Practice
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Figure 5: Dual innervation of the oesophagus. The oesophagus is dually innervated by the vagal and spinal nerves. The spinal nerves enter
the central nervous system (CNS) through the dorsal root ganglion of the spinal cord from C1 to L2. The vagal aﬀerents travel with the main
branch of the vagal nerve, primarily entering the CNS via the nodose and jugular ganglia of the vagal nerve and synapsing in the nucleus of
the solitary tract.
the sympathetic or parasympathetic nerves to enter the
spinal cord. Aﬀerents mediating sensory information travel
mainly together with the sympathetic nerves, whereas those
traveling together with the parasympathetic nerves are
mainly involved in secretion, motor, and regulatory reﬂexes
that do not reach consciousness [17]. In the oesophagus,
however, nerves traveling together with the vagal nerves also
transmit pain [21], and there is increasing evidence for pain
transmission via vagal aﬀerents from other segments of the
gut [22]. These vagal aﬀerents have their cell body and ﬁrst
synapse located in the nodose and jugular ganglia, from
wherethesecond-orderneuronsprojectcentrallytosynapses
in the nucleus of the solitary tract in the brain stem [23]. The
vagalaﬀerentsareabletoexertbothinhibitoryandexcitatory
inﬂuencesonspinalnociceptivetransmissionandmodifythe
conscious sensation [24].
The enteric nervous system (ENS) is present in most of
the GI tract including the oesophagus. It is closely related
to the central nervous system (CNS) and the autonomic
nervous system. The ENS is a local minibrain with reﬂexes
and a library of information for diﬀerent patterns of gut
behaviour (Figure 2)[ 25]. The major functions are control
of ﬂuid and electrolyte transport, motility, and reﬂexes. The
ENS is considered a subdivision of the autonomic nervous
system [26]. However, unlike other autonomic ganglia
that are mainly relay stations, the ENS has mechanisms
for independent processing of information like the CNS.
Hence, it is working with three functional categories of
neurons identiﬁed as sensory, inter, and motor neurons.
Vagal, but also sympathetic nerves are able to modulate the
functions of the ENS via neural synapses, and control of the
sensory receptors [26–29]. Furthermore, motility changes
are frequently seen during anxiety and stress [26, 30].
2.4. Central Pain Processing. From the spinal cord, pain
transmits to the brain through several distinct pathways
(Figure 1). Most aﬀerents travel in the spinothalamic tract to
the thalamus. From the thalamus projections to the insula,
hypothalamus, and amygdala as well as to higher cortical
levels such as cingulate and prefrontal cortices have been
described [18, 31]. Insula has an important function for
integrating the visceral sensory and motor activity together
with limbic integration and is particularly important in
pain perception from the gut [32]. The anterior cingulate
cortices and prefrontal cortices are a part of the medial
pain system, which mediates the aﬀective, emotional, and
cognitive components of the pain experience [31, 33]. In
addition to the spinothalamic tract, some aﬀerents ascend
in the spinoreticular tract mediating arousal and autonomic
responses through interaction with the reticular formation.
Finally, aﬀerents ascend in the spinomesencephalic tract,
which relates to a complex neuronal network in the brain
stem involved in endogenous pain modulation [18].
The pain system has several inherent mechanisms
whereby inﬂowing pain signals can be modulated. The
multiple complex pathways involved in this modulation
comprise both spinal and supraspinal regions. In particular,
connections between these sites, commonly referred to as the
descending modulatory pain pathways, play a central role
[34,35].Painmodulationcanleadtoeitheranincreaseinthe
transmission of pain impulses (facilitation) or a decrease in
transmission (inhibition). The balance between these states
ultimatelydeterminesthequalityandstrengthofpainsignals
leading to pain perception in the brain. Alterations in the
stateofdescendingmodulatorypathwaystowardsfacilitation
havebeenassociatedwiththetransitionofacuteintochronic
pain [36].
2.5. Sensitisation
2.5.1. Peripheral Sensitisation. Peripheral nociceptor sensi-
tisation underlies the hyperalgesia that develops imme-
diately around an injury site. Analogous to mechanisms
documented in the cutaneous system, oesophageal aﬀerent
ﬁbres may become sensitised by endogenous chemicals. This
results in an increase in their responsiveness to a given
stimulus and/or an increase in the spontaneous activity
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nociceptors sensitise, both low- and high-threshold ﬁbres in
the viscera can undergo sensitisation [22, 38]. Upon local
oesophageal inﬂammation, caused by, for example, acidic
reﬂux, various inﬂammatory mediators including protons,
prostaglandins, serotonin, and histamine are released. These
reduce the perception threshold of primary aﬀerents and
recruit previously silent nociceptors (Figure 2). This again
leads to increased aﬀerent activity to the spinal cord and
exacerbation of the pain [39]. Furthermore, an upregulated
expression of nociceptors such as sodium channels, TRPV1,
ASICs, and purino receptors are seen during inﬂammation.
As a consequence of all of these changes, the pain sensitivity
at the site of inﬂammation is increased [40, 41]. In human
experimental studies, sensitisation of the oesophagus has
been induced by mucosal perfusion of hydrochloric acid and
capsaicin [5, 42, 43].
2.5.2. Central Sensitisation. Enhanced spinal input from, for
example, oesophageal inﬂammation can activate intracellu-
lar signalling cascades within the spinal dorsal horn neurons.
This results in an increased synaptic eﬃcacy and is known as
central sensitisation [39]. Deep pain and visceral pain input
to the spinal cord are more potent than cutaneous pain in
the induction of central sensitisation [39]. Simpliﬁed, the
input leads to the activation of the N-methyl-D-aspartic acid
receptor and results in changes of the resting potential of the
second-order neuron [18]. It is thus rendered more likely
to ﬁre when stimulated by the chemical transmitters. This
is thought to be a major factor of central sensitisation [44].
Blocking the N-methyl-D-aspartic acid receptor has been
shown to prevent experimentally acid-induced central sensi-
tisation [44]. This eﬀect is used clinically, where antagonism
of the receptor during operations leads to less postoperative
pain [45].
2.5.3. Viscero-Visceral Hyperalgesia. Viscero-visceral hyper-
algesia is a complex form of hypersensitivity probably
explained by more than one mechanism. Since this phe-
nomenon takes place between visceral organs which share
their central aﬀerent termination, it is plausible that central
sensitisation play an important role [46]. Animal experi-
ments as well as human experimental studies have shown
that convergence to the same second order neuron of
aﬀerents from diﬀerent organs exists [43, 47–49]. Also, our
group has shown that oesophageal perfusion with acid and
capsaicin increased the sensitivity in the rectum and that the
referred pain areas to duodenal stimulation were increased
[50–52]. Besides changes at the spinal level, changes in the
cortical processing of pain may be involved in these mecha-
nisms [53]. The widespread visceral hypersensitivity in func-
tional GI disorders (irritable bowel syndrome, functional
dyspepsia, etc.) may be due to this mechanism [54–56].
Viscero-visceral hyperalgesia may explain the epidemio-
logical ﬁndings that several clinical conditions with organic
diseases show evidence of increased pain from other organs
(Figure 4). This was recently investigated in patients suﬀer-
ing from a combination of either coronary artery disease
and gallbladder stones or inﬂammatory bowel disease and
dysmenorrhoea [57]. It was shown that a patient having
more coexisting visceral pain conditions with common
spinal projection generated more symptoms from the other
pain condition. Besides, eﬀective treatment of one condition
signiﬁcantly improved symptoms from the other [57].
3. Sensation in Oesophageal Disorders
3.1.TheOesophagealMultimodalPainModel. Mostinforma-
tion of visceral pain physiology comes from animal studies.
However,humanexperimentalpainmodelshavebeenexten-
sively used in visceral pain studies to elucidate the sensory
properties of the gut, that is, the eﬀects of age, gender,
and menstrual cycle on pain as well as diﬀerences in the
sensitivity of several parts of visceral hollow organs [58–60].
Models including the Barostat based on balloon distension,
the Bernstein test (in which acid or saline is perfused in the
oesophagus), and electrical stimulation of the oesophagus
have been used for many years [58, 61]. The problem with
these models is that only one or two pain modalities can be
examined with each model, for example, pain to electrical
current and acid. If several modalities are to be examined,
it would require multiple intubations, most likely resulting
in a dropout of volunteers. The multimodal pain model was
developed to overcome these obstacles. With one catheter
and one intubation only, it is possible to stimulate the
oesophagus with distension, cold, heat, electrical current,
and liquid chemicals (Figure 6)[ 16]. The main advantage
of the model is that it allows a diﬀerentiated assessment of
the superﬁcial and deep structures of the gut wall, activation
of diﬀerent nerve ﬁbres, and peripheral as well as central
pain mechanisms. The model is reproducible and has been
widely used to understand basic sensory mechanisms in the
oesophagus as well as mechanical properties. The validity of
the model was conﬁrmed in studies where the model was
usedtoexplorethepathophysiologyofoesophagealdisorders
such as ERD and NERD, BO, and noncardiac chest pain
(NCCP) [12, 62–65]. The ﬁndings in these and other studies
on oesophageal sensitivity are summarised in Table 1.
3.2. Neurophysiological Assessment. In most experimental
studies, assessment of pain has relied on indirect measure-
ments of self-reported pain. These subjective measurements
have been improved with the use of validated psychophysical
scales like the visual analogue scale, the McGill pain ques-
tionnaire, and the Gracely pain scale [19]. As opposed to the
subjective assessment of pain, neurophysiological assessment
provides an objective way to characterise the pain response.
In humans, the brain response to experimental oesophageal
pain has been studied using positron emission tomography
(PET), functional magnetic resonance imaging (fMRI), and
methods based on evoked brain potentials. In PET studies,
painful dilatation of the oesophagus was shown to activate
mainly the anterior insular cortex and anterior cingulate
gyrus [66]. In studies based on fMRI, parallel ﬁndings have
been reported [66, 67].
Although PET and fMRI possess a high spatial resolution
(millimetres), they are hampered by a poor temporal reso-
lution (seconds). Thus, the retrieved brain response using
these methods corresponds to rather late events that may6 Gastroenterology Research and Practice
Table 1: Sensitivity change to diﬀerent stimuli in various oesophageal disorders relative to healthy controls.
Disorder Acid and/or capsaicin Distension Heat Central sensitisation
ERD ↑ [15] ↓ [82] ↑ [10] ↑ [10]
NERD
↑ [12]; ↑ in pH−,→ in pH+
[83]
↓ [12] ↑[12] ↑ [12]
Barrett’s oesophagus ↓ [83–85] ↓ [64] ↓[64] → [64]
FCP/FH ↑↑ [86] ↑ [87–89]?↑ [48, 65]
Eosinophilic oesophagitis ↑ [62] → [62] →[62] → [62]
↑:increased;↑↑:highlyincreased;↓:decreased; →:nochange;?:insuﬃcientdata;ERD:erosivereﬂuxdisease;NERD:nonerosivereﬂuxdisease;FCP:functional
chest pain; FH: functional heartburn; pH−/+: negative/positive 24-hour oesophageal pH monitoring (positive if time with pH<4i sa b o v e5 % ) .
Temperature sensor
Pressure channel
Circulation channels
Impedance electrode
Hole for acid perfusion (•)
Electrodes for stimulation
Perfusion channel for HCl
Wires for electrical stimulation
Bag and holes (￿) for water perfusion inside
the catheter
Figure 6: The multimodal probe. The probe is placed in the lower oesophagus with the bag located 8cm above the oesophagogastric
junction. The probe can be used to give painful stimuli by mechanical inﬂation of the bag with saline, giving a weak electrical shock or
circulating heated or cold water inside the probe. Hyperalgesia can be evoked with acid and/or capsaicin infusions through a hole proximal
to the bag. This way, the oesophageal sensitivity to diﬀerent pain modalities can be investigated in one procedure.
be related to arousal and attention rather than pain. On the
contrary, evoked brain potentials detect neuronal activity in
realtimewithaveryhightemporalresolution(milliseconds).
Using this technique, the sequential brain activity following
electrical stimulation of the oesophagus was determined in
as t u d yf r o mo u rg r o u p[ 68]. Furthermore, studies based
on advanced evoked potential analysis have shown evidence
of changes in central pain processing following electrical
stimulation of the oesophagus. The ﬁndings have been
made in healthy volunteers and in patients suﬀering from
functional chest pain (among others [69], see also later
sections).
4. ClinicalAspects of Oesophageal Disorders
The clinical picture of oesophageal disorders depends on
the pathophysiology responsible for their development. In
some diseases, for example ERD, excess oesophageal acid
exposure is thought to be the main pathophysiological
factor underlying their development [70]. Hence, ERD is
considered an organic disorder which should be cured by
removing the main cause of the disease, namely, oesophageal
acid exposure. In contrast, functional chest pain (FCP)
symptoms are believed to be caused by some kind of
oesophageal hypersensitivity without objective pathological
ﬁndings, that is, a functional disorder as the name suggests
[71–74].
4.1. Nonerosive and Erosive Reﬂux Disease. GORD is deﬁned
as chronic mucosal damage or typical symptoms of reﬂux
disease, which reduce quality of life, combined with the
retrograde reﬂux of gastric contents into the oesophagus
[75]. The typical symptoms include heartburn, regurgita-
tion, and/or chest pain; furthermore, many patients consider
heartburn a painful feeling. GORD is a very common
disorder with up to 30% of the European population
reporting heartburn and/or acid regurgitation during the
previous 12 months [74].
Usually, GORD is divided into ERD and NERD. When
classiﬁed according to endoscopy, 24-hour pH proﬁle and
symptom-reﬂux association indices, recent studies have
revealed that up to 70% of the GORD patients have NERD.
However, the quality of life impairment in patients with
NERD is comparable to that in patients with ERD [76].
Since the symptoms in reﬂux disease are highly variable
and poorly understood, no general relation seems to exist
in patients with GORD between the symptoms and severity
of the disease categorised endoscopically [74, 77, 78].
Adding 24-hour oesophageal impedance monitoring to the
pH measurement has given the possibility of identifyingGastroenterology Research and Practice 7
Table 2: Clinical characteristics of diﬀerent reﬂux disorders.
Disease Visible lesions on
endoscopy 24h pH Typical symptoms Symptom response to
PPI
Symptom response to
placebo
ERD Yes (erosions) Positive Heartburn Very good (app. 60 to
80%) [90, 91]
Very poor (app. 10%)
[90, 92]
NERD No Variable Heartburn
Intermediate to good
(app. 40% [90] to 70%
[93])
Very poor (app. 15%)
[90, 92]∗
Barrett’s oesophagus Yes (Barrett mucosa) Positive Heartburn, none Intermediate ?
FCP/FH No Negative Heartburn, chest pain Intermediate (app. 50%)
[94]
Very poor (app. 5%)
[94]
∗Including FCP; 24-hour pH: typical results of 24-hour oesophageal pH monitoring (positive if time with pH<4 is above 5%); PPI: proton pump inhibitor;
app.: approximately; ERD: erosive reﬂux disease; NERD: nonerosive reﬂux disease; FCP: functional chest pain; FH: functional heartburn; ?: insuﬃcient data.
subgroups of these patients who have reﬂux of nonacid or
weaklyacidicgastriccontents[79].Inthisway,somepatients
who were earlier classiﬁed as having no signiﬁcant reﬂux can
now be correctly classiﬁed. However, the clinical importance
of this is uncertain, especially in NERD patients [80].
Conclusively, in many patients the exact cause of symp-
toms remains unclear. Some patients will, however, fulﬁl
the deﬁnition of functional oesophageal disorders, see next
section.
4.2. Functional Oesophageal Disorders and Chest Pain
4.2.1. Deﬁnition and Prevalence of Functional Disorders. Ac-
cording to the Rome III criteria, FCP is deﬁned as Midline
c h e s tp a i no rd i s c o m f o r tt h a ti sn o to fb u r n i n gq u a l i t y ,a b s e n c e
of evidence that gastrooesophageal reﬂux is the cause of the
symptom, and absence of histopathology-based oesophageal
motility disorders. The criteria must be fulﬁlled for the last
6 months with symptom onset at least 3 months prior to
diagnosis [81]. Another group of patients have functional
heartburn(FH),forwhichtheRomeIIIcriteriaarethesame,
except that their discomfort or pain is located retroster-
nally and is described as burning. These patients probably
resemble the ERD and NERD patients more than FCP and
show better improvement on proton pump inhibitor (PPI)
therapy. Functional chest pain has also been termed NCCP
and unexplained chest pain, terms that according to the
Rome III criteria are somewhat resembling FCP but also
include the deﬁnition of FH. Due to these similarities and
the fact that few studies have examined them separately, FH
isincludedinFCPinthisreview.Someclinicalcharacteristics
of FCP are summarised in Table 2.
The prevalence of FCP is much debated, and few studies
have used the Rome III criteria. With widely varying criteria,
the prevalence has been estimated anywhere between 2
[96] and 46% [97]. Furthermore, the disease accounts for
approximately 2–5% of presentations to emergency depart-
ments and 5% of presentations to primary care physicians
[98, 99] and therefore has major implication on any health
care system. Before the diagnosis of FCP is established,
patients should undergo thorough evaluation (cardiac and
gastroenterological) to exclude other diseases causing the
pain [99, 100].
4.2.2. Possible Mechanisms for Hypersensitivity in Functional
Chest Pain. Formerly, oesophageal hypersensitivity to oth-
erwise physiological stimuli was considered a likely origin
for FCP. Hence, the disorder has been termed “irritable
oesophagus” or “acid-hypersensitive oesophagus” [71–73].
Nowadays, symptoms associated to reﬂux events are con-
sidered a part of the spectrum of symptomatic GORD
[100]. In several studies, Rao et al. have reported increased
oesophageal sensitivity to balloon distension in patients
classiﬁed with NCCP [87–89]. However, our group has later
performed a similar study using multimodal oesophageal
stimulation, applying a protocol better designed to detect
the pain response to oesophageal distensions. We did not
ﬁnd hyperalgesia at baseline in NCCP patients but did
ﬁnd lowered pain thresholds to distension and increased
referred pain areas after sensitisation with acid perfusion
[101].Arecentstudysimilarlyfoundloweredpainthresholds
after acid sensitisation in FH patients compared to healthy
controls [102]. Since referred pain inevitably involves central
mechanisms, this is a strong indicator of central sensitisation
inNCCP/FCP/FHpatients.ThiswasalsoproposedbySarkar
et al., who found secondary viscero-visceral and viscero-
somatic hypersensitivity to painful stimuli after oesophageal
acid perfusion in NCCP patients [48]. Furthermore, sev-
eral neurophysiological studies have analysed evoked brain
potentials after painful oesophageal stimulation [43, 49, 69,
103–105] in NCCP patients. They have found consistent
results indicating abnormal central pain processing and
sensitisation. Furthermore, others have found the activation
of autonomous reﬂexes, primarily increased vagal tone,
following acid stimulation [103, 106]. Besides central sensi-
tisation, peripheral nerve sensitisation is probably present in
FCP as well as in other oesophageal pain disorders [107], but
f e ws t u d i e si nt h i sa r e ah a v eb e e nd o n e .
4.3. Barrett’s Oesophagus. Barrett’s oesophagus (BO) is a
metaplastic condition in the oesophagus, in which the
squamous epithelium is replaced with columnar epithelium,
so far considered to arise due to excess gastro-oesophageal
reﬂux [108]. Further clinical characteristics are summarised
in Table 2. The prevalence is rising and probably around
1.6% in the general population of Western countries [109].
The most important clinical aspect of the disorder is8 Gastroenterology Research and Practice
the largely increased risk of oesophageal adenocarcinoma,
possibly as much as 125 times compared to the general
population [110].
4.3.1. Sensitivity in the Oesophagus. Patients with BO are
most likely hyposensitive to oesophageal stimuli, but the
power of evidence for the hyposensitivity is variable between
the diﬀerent stimulus modalities (Table 1). Several studies
have found indications of lowered acid sensitivity in patients
with BO. This is true for clinical [13, 84]a sw e l la se x p e r -
imental studies [14, 111, 112]. Using the multimodal pain
model, our group investigated the sensitivity in patients with
BO. We showed hyposensitivity to mechanical distension
in the lower (metaplastic) part of the oesophagus and
hyposensitivity to both mechanical and heat stimulation
in the normal mucosa in the mid-oesophagus [64]. This
could indicate that the sensory abnormalities precede the
disease rather than being a consequence of the metaplasia.
Furthermore, no indication of central involvement in the
oesophageal hyposensitivity was found [64]. Similar results
of hyposensitivity in BO to oesophageal balloon distension
were found in another study [83]. Hence, a dysfunction of
the aﬀerent sensory pathways could be one explanation for
hyposensitivity and a possible pathogenetic factor in BO.
Potentially, a number of acid receptors could be involved in
the hyposensitivity [113]. Among these, the best candidate is
the TRPV1 receptor which has previously been shown to be
s e n s i t i v et oh e a ta sw e l la sa c i d[ 11, 114].
4.3.2. Impaired Acid Clearance. Several indications exist that
patients with BO have an impaired ability to clear reﬂuxed
acid from the oesophagus. An excess acid exposure on
24-hour pH measurement has previously been shown in
BO compared to both healthy controls and other GORD
patients [70, 115]. Excess acid exposure in BO could indicate
an impaired ability to clear reﬂuxed acid. Furthermore, at
least one TRPV1 receptor-mediated oesophageal peristaltic
reﬂex protecting the mucosa from harmful stimuli has been
shown to be impaired in patients with BO [116]. Finally,
oesophageal motility disorders including lower oesophageal
sphincter insuﬃciency and decreased peristaltic amplitudes
have been shown to be overrepresented in patients with
BO [117]. These ﬁndings could be part of the possible
explanation for this impaired acid clearance.
5. Treatment of Oesophageal Pain and
Related Symptoms
5.1. Acid Suppression. Overall, PPIs are the most eﬀective
acid-suppressive drugs available and are the drug of choice
for GORD (Table 2). Symptoms such as painful heartburn
and isolated chest pain have been shown to respond very fast
to treatment with PPIs [93, 118, 119].
A meta-analysis by Khan et al. including 35.978 patients
with erosive oesophagitis found PPIs to be roughly 4 times
as eﬀective as placebo and twice as eﬀective as histamine 2
receptor antagonists in healing erosive oesophagitis [118].
Also, they showed a modest, but signiﬁcant eﬀect on
the healing of oesophagitis when doubling the PPI dose,
Table 3: Potency of diﬀerent PPIs as measured by eﬀect on mean
intragastric 24-hour pH. Figures from [95].
PPI Relative potency compared to omeprazole
Rabeprazole 1.82
Esomeprazole 1.60
Omeprazole 1.00
Lansoprazole 0.90
Pantoprazole 0.23
with a number needed to treat of 25 [118]. However, in
the treatment of heartburn symptoms without endoscopic
lesions,theeﬀectofPPIsislessconvincing.Moststudieshave
included NERD and FCP as a whole, despite the previously
mentioned diﬀerences between these groups. In a meta-
analysis,Hiyamaetal.foundasigniﬁcantsymptomimprove-
ment rate of 68% on PPI treatment in NERD patients, but
the results of the included studies were conﬂicting [93]. In
another meta-analysis, Cremonini et al. found PPI treatment
to be superior to placebo on symptom improvement in
NERD, with a number needed to treat of 3 [119]. On
the opposite, Dean et al. concluded that the diﬀerence in
symptom response rates between PPIs and placebo (the
therapeutic gain) was only 27% in NERD (compared to 48%
in ERD) [90].
A probably important factor inﬂuencing the response
to PPI treatment in NERD patients is the degree of
distal oesophageal acid exposure measured with 24-hour
oesophageal pH. A close relationship was shown between
long acid exposure time and the response to PPIs in a large
clinical trial [120].
Doubling the dose of PPI using a standard dose twice
daily is used in certain cases. In the treatment of ERD, this is
supported by reasonable evidence with a NNT of 25 for the
doubling of dose [118].However,whentreatingNERD,inan
attempt to relieve patients not responding to conventional
doses of PPI, the evidence supporting the doubling of dose
is lacking [91]. Yet some recommendations, including those
of the American Gastroenterological Association Institute,
recommend trying out double dose of PPI for persistent
oesophageal symptoms, regardless of endoscopic ﬁndings
[121].
When considering which PPI to use, price and degree of
symptoms must be taken into consideration. The potency of
the diﬀerent PPIs is somewhat varying, but the overall eﬃ-
cacy is good. A meta-analysis by Kirchheiner et al. including
57 clinical studies [95] found relative potencies compared to
omeprazole between 0.23 and 1.82 for the currently available
PPIs (Table 3). Despite the diﬀerences in theoretical potency,
no major diﬀerences in regard to the clinical eﬀect have been
found between the diﬀerent PPIs [91].
When it comes to histamine 2 receptor antagonists, sev-
eral studies have found these to be superior to placebo (but
inferior to PPIs) in healing reﬂux oesophagitis, including the
above-mentioned meta-analysis [118, 122]. Therefore, these
drugs remain primarily a supplement to the PPIs but can be
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symptoms are present or due to economic considerations
[91, 123]. Histamine 2 receptor antagonists have also been
used in nightly reﬂux where PPIs are less eﬃcient, although
tachyphylaxis limit their long-term use [122].
Conclusively, the primary choice of acid suppressive
treatment in patients who fulﬁl the criteria for GORD,
regardless of other characteristics, should be a PPI of
any choice in the standard dose. This said, those who
have normal oesophageal mucosa on endoscopy (NERD)
and especially those with negative 24-hour pH (FCP and
FH patients according to the previous deﬁnitions) beneﬁt
less from acid-suppressive treatment than ERD patients.
However, they most likely still have a better response to
PPIs than to placebo [91, 92, 121]. Histamine 2 receptor
antagonistscanalsobeusedassupplementtoPPIsorbecause
of the lower price but are less eﬀective.
5.2. Surgery. Surgical treatment of reﬂux is more eﬀective
than medical treatment of reﬂux and pain. The primary
surgical method is Nissen fundoplication, in which the gas-
tric fundus is wrapped around the oesophagus to create an
artiﬁcial valve to support the insuﬃcient upper oesophageal
sphincter. A meta-analysis including 1232 patients showed
improvement in quality of life, GORD-related symptoms,
and 24-hour pH up to 1 year after an operation with
Nissen fundoplication compared to medical treatment with
PPIs [124]. However, data on long-term outcome were
insuﬃcient, and side eﬀects should also be taken into
consideration. Most important side eﬀectsin patients treated
surgically are dysphagia (6%), risk of reoperation (up to
7% within 3 years), and diﬀerent abdominal symptoms such
as inability to belch, bloating, and diarrhoea (up to 36%)
[91, 125].
5.3. Other Drugs. Transient lower oesophageal sphincter
relaxations have been shown to be a major contributor to
acidic and nonacidic gastro-oesophageal reﬂux, especially
in NERD patients [126, 127]. Several drugs have been
developed to reduce the number of these relaxations. These
include gamma amino butyric acid B (GABAB) agonists,
metabotropic glutamate receptor antagonists and cannabi-
noid receptor 1 agonists, which, hence, can be used to
treat reﬂux and associated chest pain. So far, only GABAB
agonists have proven clinically valuable, whereas the two
latter still await clinical studies [127]. Baclofen, a speciﬁc
GABAB agonist, acts on the central level and has been shown
to reduce the rate of transient lower oesophageal sphincter
relaxations and increase lower oesophageal sphincter basal
tone. Besides, it has proven eﬀective on clinical parameters
such as oesophageal acid exposure, nonacid reﬂux, bile
reﬂux, and symptom improvement [127]. Baclofen has
noticeable side eﬀects such as dizziness and nausea, due to
the central action. Despite this and a short half life of 3-
4 hours, it has been used in the treatment of GORD [128,
129]. Another promising GABAB agonist is lesogaberan,
which has a theoretical eﬀect similar to baclofen, but acts
primarily in the periphery. So far, lesogaberan has only been
investigated in one clinical study in GORD patients, which
foundsigniﬁcantreductiononthenumberoftransientlower
oesophageal sphincter relaxations and reﬂux episodes and
side eﬀects on placebo level [130].
5.4. Lifestyle Modiﬁcation. The evidence supporting a ben-
eﬁcial eﬀect of lifestyle interventions for the treatment
of oesophageal pain disorders is sparse. A comprehensive
review by Kaltenbach et al. found weight loss and head
of bed elevation to be the only certain factors to improve
the course of GORD [131]. Both were shown to improve
symptoms and acid exposure time measured by oesophageal
24-hour pH. In the same review, however, neither smoking,
alcohol, nor high-fatty meals showed any eﬀect on clinically
measurable variables. This is somewhat surprising, since
there is physiological evidence that these three factors do
increasethenumberoftransientloweroesophagealsphincter
relaxations [131].
Weight loss has been found to have a probable positive
eﬀect on GORD [131, 132]. However, this was based on
symptom assessment from questionnaires, whereas more
robust signs of improvement such as oesophageal 24-hours
pH-measurement failed to show an eﬀect. Despite the lack
of evidence, guidelines, for example the American Gastroen-
terological Association [121, 122], recommend avoiding late
meals, speciﬁc foods, alcohol, or speciﬁc activities in selected
patients,especiallyinpatientswhohaveexperiencedthatthis
is eﬀective in controlling their symptoms.
5.5. Symptomatic Pain Treatment in Oesophageal Disorders.
FCP should not be treated as such before a thorough evalua-
tion has excluded other causes of the patient’s symptoms. If a
diagnosis of a functional oesophageal disorder is established,
the approach to the patient should be based on treatment of
symptoms. Patients with heartburn and negative acid expo-
sure have greater anxiety and somatisation scores than those
with veriﬁed reﬂux [100]. This means that a psychological
approach including explanation of the mechanism behind
and reassurance of the diagnosis probably helps the patient
tocopebetterwiththesymptoms.Psychologicalintervention
in the form of cognitive behavioural therapy undertaken by a
psychologist or psychiatrist has been demonstrated eﬀective
in patients classiﬁed with NCCP in clinical trials [133–135].
When it comes to pharmacological treatment, conven-
tional pain treatment is only one option. Here, the principle
of the analgesic ladder applies [136]. This means that
paracetamol should be used as ﬁrst-line analgesic. Nons-
teroid anti-inﬂammatory drugs are the usual second step in
pain treatment, but caution should be taken when treating
patients with GI diseases because of the risk of bleeding and
strictures. If patients have chest pain due to musculoskeletal
disorders, NSAIDs are the natural choice. However, in risk
groups such as previous ulcer or old age, parallel treatment
with a PPI is recommended. If paracetamol is not suﬃcient
and GI disease is present, a weak opioid can be chosen. In
other diseases with chronic pain, this has been demonstrated
more eﬀective than morphine and with less side eﬀects
[137].
Other drugs with eﬀect on FCP are tricyclic antide-
pressants and selective serotonin reuptake inhibitors, which
have been demonstrated eﬀective on functional GI disorders10 Gastroenterology Research and Practice
including FCP in controlled trials [94, 100, 135, 138].Drugs
developed for epilepsy such as gabapentin and lamotrigine
can also be eﬀective in certain cases. On a more experimental
level and in an open label study, theophylline was shown to
increase the pain threshold to experimental pain in patients
with functional chest pain compared to placebo [89]. If a
primary motility dysfunction is suspected, treatment with
nitrates or calcium channel blockers can be considered
[139].
5.6. Summary of Treatment Recommendations. In summary,
when approaching a patient with reﬂux symptoms suspected
for GORD, the general strategy is to start with a short
course (e.g. 4 weeks) of PPI in the standard dose as a
diagnostic test. This has been shown to be the most cost-
eﬀective and time-saving approach with a good sensitivity
as well as speciﬁcity in diagnosing NERD [99, 119, 140].
If the patient responds, the PPI dose is tapered to the
lowest dose relieving the symptoms. In case of treatment
failure, other evaluation such as endoscopy, oesophageal
24-hour pH-impedance monitoring, and high-resolution
oesophageal manometry should be undertaken. Depend-
ing on the results of these tests, treatment adjustment
can be considered. Surgery should probably be reserved
for younger patients deeply troubled by their symptoms
despite high-dose PPI treatment, and only after careful
evaluation has concluded that gastro-oesophageal reﬂux is
the true cause of the symptoms. Lifestyle modiﬁcations
can always be considered, but recommendations should be
individualised since no parameter is overall eﬀective. In
functionaloesophagealdisorders,psychologicaltherapysup-
plemented by pain treatment with analgesics should be the
choice.
6. Conclusion
Disorders of the oesophagus show heterogeneous char-
acteristics in relation to the pathogenesis and symptoms
and therefore also require an appropriate investigation and
a treatment adjusted to the ﬁndings. Methods like the
multimodal model for oesophageal pain characterisation
have been developed to supplement the conventional inves-
tigations such as oesophageal 24-hour pH and impedance
measurement and manometry. Furthermore, neurophysi-
ological assessment such as PET, fMRI, and analysis of
evoked brain potentials can potentially contribute to the
clinical evaluation of these complex disorders in the future.
Treatment should be directed against the cause of the
disease. When for example, gastro-oesophageal reﬂux is the
cause of symptoms, the recommended treatment is acid
suppression with primarily PPIs and in rare cases surgery.
Handlingoffunctionaloesophagealdisordersshouldinclude
acid suppression and analgesics but also consider anti-
depressants and psychological assessment and treatment.
Lifestyle changes as treatment of oesophageal disorders
can also be tried but should be directed according to the
individual eﬀe c to ns y m p t o m si ne a c hp a t i e n t .
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